All In Biotech

Drug Trial Radar · NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Nov 6, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

Conditions

  • Extensive Stage Lung Small Cell Carcinoma
  • Lung Small Cell Carcinoma, A Subtype
  • Lung Small Cell Carcinoma, I Subtype
  • Lung Small Cell Carcinoma, N Subtype
  • Lung Small Cell Carcinoma, P Subtype

Interventions

  • Biospecimen CollectionProcedure

    Undergo tissue and blood sample collection

  • CeralasertibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • DurvalumabBiological

    Given IV

  • EtoposideDrug

    Given etoposide

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MonalizumabBiological

    Given IV

  • Platinum CompoundDrug

    Given platinum compound

  • Positron Emission TomographyProcedure

    Undergo PET/CT scan

  • SaruparibDrug

    Given PO

  • Thoracic Radiation TherapyRadiation

    Undergo thoracic radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Screen success rate (Screening)Time frame: Up to 3 years
  2. Progression-free survival (PFS) (Cohort A)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years
  3. PFS (Cohort B)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years
  4. PFS (Cohort C)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years

Locations

148 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Eisenhower Medical Center

    Rancho Mirage, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Memorial Hospital North

    Colorado Springs, Colorado · Recruiting

  • Poudre Valley Hospital

    Fort Collins, Colorado · Recruiting

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado · Recruiting

  • Lutheran Hospital - Cancer Centers of Colorado

    Golden, Colorado · Recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Recruiting

  • Medical Center of the Rockies

    Loveland, Colorado · Recruiting

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut · Recruiting

  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

    Savannah, Georgia · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Grayslake Outpatient Center

    Grayslake, Illinois · Recruiting

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • Northwestern Medicine Oak Brook

    Oak Brook, Illinois · Recruiting

  • Northwestern Medicine Orland Park

    Orland Park, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • Mary Greeley Medical Center

    Ames, Iowa · Recruiting

  • McFarland Clinic - Ames

    Ames, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Recruiting

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.